OptiBiotix Health PLC LPLDL® US manufacturing and supply agreement (3381D)
October 09 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3381D
OptiBiotix Health PLC
09 October 2018
9 October 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
LP(LDL) (R) US manufacturing and supply agreement
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it has entered into a manufacturing
and supply agreement with US Pharma Lab Inc. ("USPL"). This is the
first agreement completed through its newly formed subsidiary
ProBiotix Health Ltd, as previously announced on 24 September
2018.
USPL, established in 1997, is a family owned and operated
business with facilities in the US, India and China, and employing
more than 600 people globally. With a focus on handling challenging
ingredients such as probiotics, USPL is known as the partner of
choice where science meets quality. The US (New Jersey)
manufacturing footprint includes a purpose build probiotic
manufacturing facility and covers over 100,000 sq ft with
Pharmaceutical GMP certification, which offers the possibility to
utilise LP(LDL) (R) in pharmaceutical applications.
USPL has a strong reputation and leading expertise in developing
unique formulations and presentations containing probiotic strains
for the nutraceutical marketplace. Under the terms of the
agreement, USPL is granted non-exclusive rights to manufacture and
supply formulations containing OptiBiotix's LP(LDL) (R) strain. It
is an important step in a business to business (B2B) strategy of
bringing OptiBiotix's science together with partner's expertise and
market reach to create multiple product opportunities to serve
consumer healthcare and pharmaceutical markets around the
world.
This agreement gives a strategic access to the world's largest
probiotic market, with an estimated retail value of $7.1 billion
per annum. The US is one of the largest and fastest growing
probiotic markets in the world, with supplements alone accounting
for $2.06 billion sales, with a projected 55% growth to $3.3
billion by 2021.
Per Rehne, Commercial Director of OptiBiotix, commented: "We are
pleased to announce this agreement with USPL for the manufacturing
and supply of formulations containing OptiBiotix's LP(LDL) (R) .
This agreement extends our product offering in multiple
presentations containing OptiBiotix's LP(LDL) (R) and creates an
opportunity to access the US food supplement market with an
established industry supplier. We will showcase the first
formulation as a result of this agreement at Supply Side West in
Las Vegas in November. We chose USPL due to its purpose build
probiotic facilities, industry experience and reputation. We
believe our strategy of identifying and building partnerships with
industry leading partners like USPL, provides the best opportunity
of rapidly building revenue streams, and establishing LP(LDL) (R)
as a leading global brand."
Amol Luhadia , Executive Vice President of USPL, commented: "In
partnering with ProBiotix Health, USPL will develop a line of
shelf-stable probiotic formulations designed to enhance the
benefits of LP(LDL) (R) and we're excited about the prospects of
this. This agreement will offer innovative concepts with
complementary dietary ingredients to the growing US market segment
of cholesterol and blood pressure reduction, as well as
cardiovascular risk. We believe this agreement gives a unique
opportunity to make LP(LDL) (R) available in multiple formulations
to the US food supplement industry."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRFKFDQPBDDOKK
(END) Dow Jones Newswires
October 09, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024